Quality of Life Assessment of Caregivers of Patients With Multiple Myeloma
NCT ID: NCT07276230
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
27 participants
INTERVENTIONAL
2026-02-01
2027-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study procedures :
1. During the hematology consultation, the study will be presented to the caregiver identified by the patient (between Day -7 and Day 0). After receiving full oral and written information, the caregiver's free, written, and informed consent will be obtained prior to participation.
2. After providing written informed consent to participate in the study, the caregiver will attend an individual interview at Day 0 with a nurse to complete a Shared Educational Assessment .The caregiver will then independently complete a self-administered questionnaire assessing quality of life using the CarGOQoL (CareGiver Oncology Quality of Life).
The Shared Educational Assessment is a discussion between the healthcare professional and the caregiver focusing on the skills to be acquired or strengthened in order to improve health and quality of life. It enables exploration and assessment of the caregiver's needs and resources in terms of :
* Acquisition of knowledge;
* Acquisition or reinforcement of self-care and coping skills, while recognizing and valuing the caregiver's own self learning efforts.
3. The group of caregivers thus constituted will attend four therapeutic education workshops. Each workshop will last approximately 1 hour and 30 minutes. Caregivers will attend two half-day sessions, participating in two workshops per session (Week 1: Workshops 1 \& 2; Week 2: Workshops 3 \& 4).
The topics addressed in the workshops are as follows:
* Workshop 1: Understanding the disease
* Workshop 2: Identifying abnormalities in biological tests and adapting the appropriate response
* Workshop 3: Understanding treatments and their adverse effects
* Workshop 4: Expressing personal experiences and feelings caregivers' satisfaction with each workshop will be assessed at the end of every session
4. At the end of the program (three months after inclusion), the caregiver will attend a follow-up consultation with the nurse to evaluate skill acquisition and will independently complete the same quality of life questionnaire (CarGOQoL) that was administered prior to the program
5. At six months, a new assessment of quality of life will be conducted using the CarGOQoL questionnaire during a telephone interview with a member of the investigative team
The questionnaire will be available in paper format, and the responses will be entered into an electronic case report form (e-CRF) using the CleanWeb system. The data will be analyzed by the Clinical Research Unit (URC).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Caregivers
Therapeutic Education and Needs Assessment Program for Caregivers of Patients with Multiple Myeloma
Therapeutic Education and Needs Assessment Program for Caregivers
Participation in a weekly therapeutic education group for 4 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Therapeutic Education and Needs Assessment Program for Caregivers
Participation in a weekly therapeutic education group for 4 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Designated by a patient followed for multiple myeloma during first-line treatment
* Providing weekly assistance to the patient (e.g., shopping, housekeeping, management of daily living activities, healthcare or hygiene support, etc.)
* Aged 18 years or older
* Fluent in French
* Affiliated with or benefiting from a social security system (excluding state medical aid - AME)
* Able to provide free, written, and informed consent
Exclusion Criteria
* Not designated by the patient as the primary caregiver
* Currently being treated for an acute medical condition
* Refusal of the caregiver to participate in the study
* Under legal protection (guardianship or curatorship)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne LE BORGNE, Mrs
Role: PRINCIPAL_INVESTIGATOR
Hospital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hématologie clinique - Pitié-Salpêtrière Hospital (APHP)
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Anne LE BORGNE, Mrs
Role: primary
Laurent Dr GARDERET, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP250083
Identifier Type: -
Identifier Source: org_study_id